|
|
This section of Hepsera.com provides healthcare professionals with comprehensive information about Hepsera® (adefovir dipivoxil) — the first choice for long-term success in treating patients with chronic hepatitis B.
|
|
 |
|
|
Hepsera is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.1
This indication is based on histological, virological, biochemical and serological responses in adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.1
To learn more about the efficacy, safety, dosing and resistance profile of Hepsera, click here.
|
|
|
|
|
- Severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis B therapy, including Hepsera. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, resumption of anti-hepatitis B therapy may be warranted.
- HIV resistance may emerge in chronic hepatitis B patients with unrecognized or untreated human immunodeficiency virus (HIV) infection treated with anti-hepatitis B therapies, such as therapy with Hepsera, that may have activity against HIV.
- Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals.
- In patients at risk of or having underlying renal dysfunction, chronic administration of Hepsera may result in nephrotoxicity. These patients should be monitored closely for renal function and may require dose adjustment.
- Dose adjustment is recommended in patients with creatinine clearance <50 mL/min.
- Since adefovir is eliminated by the kidney, co-administration of Hepsera with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either adefovir and/or these co-administered drugs. Patients should be monitored closely for adverse events when Hepsera is co-administered with drugs that are excreted renally or with other drugs known to affect renal function.
Click here for full Prescribing Information.
|